Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Obermeyer Wealth Partners

Obermeyer Wealth Partners raised its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 13.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 130,104 shares of the company's stock after buying an additional 15,220 shares during the period. Obermeyer Wealth Partners' holdings in Novo Nordisk A/S were worth $11,192,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of NVO. MayTech Global Investments LLC grew its holdings in Novo Nordisk A/S by 48.4% during the fourth quarter. MayTech Global Investments LLC now owns 377,752 shares of the company's stock valued at $32,494,000 after purchasing an additional 123,200 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Novo Nordisk A/S by 3.2% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 95,080 shares of the company's stock valued at $8,179,000 after buying an additional 2,920 shares during the period. Mmbg Investment Advisors CO. acquired a new stake in Novo Nordisk A/S during the fourth quarter worth about $1,520,000. LRI Investments LLC increased its position in shares of Novo Nordisk A/S by 1.4% during the fourth quarter. LRI Investments LLC now owns 13,060 shares of the company's stock valued at $1,123,000 after purchasing an additional 176 shares during the period. Finally, Lighthouse Investment Partners LLC lifted its position in Novo Nordisk A/S by 148.4% in the fourth quarter. Lighthouse Investment Partners LLC now owns 38,500 shares of the company's stock worth $3,312,000 after purchasing an additional 23,000 shares during the period. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $67.70 on Tuesday. The firm has a market capitalization of $303.79 billion, a PE ratio of 20.58, a P/E/G ratio of 0.90 and a beta of 0.65. Novo Nordisk A/S has a 52-week low of $57.00 and a 52-week high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The stock has a 50 day simple moving average of $68.75 and a 200 day simple moving average of $85.51.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.92. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. The firm had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $79.17 billion. Sell-side analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on NVO. Dbs Bank downgraded shares of Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. StockNews.com upgraded Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a report on Friday, April 25th. BNP Paribas began coverage on shares of Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an "underperform" rating on the stock. Finally, BMO Capital Markets restated a "market perform" rating and issued a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of "Moderate Buy" and a consensus price target of $135.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.